Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Lake Street Capital

Investment analysts at Lake Street Capital assumed coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report issued on Thursday, MarketBeat Ratings reports. The firm set a “buy” rating and a $45.00 price target on the stock.

ALGS has been the topic of a number of other research reports. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Monday, April 20th. Cantor Fitzgerald began coverage on shares of Aligos Therapeutics in a report on Thursday, May 21st. They issued an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Westpark Capital began coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They issued a “buy” rating and a $48.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Aligos Therapeutics Stock Down 2.4%

NASDAQ ALGS opened at $5.60 on Thursday. Aligos Therapeutics has a 12-month low of $5.12 and a 12-month high of $13.69. The company has a market capitalization of $34.66 million, a PE ratio of -0.64 and a beta of 2.28. The firm’s 50 day moving average is $6.76 and its 200-day moving average is $7.88.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The business had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. As a group, sell-side analysts expect that Aligos Therapeutics will post -7.47 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its stake in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in Aligos Therapeutics in the third quarter valued at approximately $99,000. HRT Financial LP acquired a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $106,000. DRW Securities LLC acquired a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $111,000. Finally, XTX Topco Ltd acquired a new stake in Aligos Therapeutics in the second quarter valued at approximately $100,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.